Open in interactive viewer → charts, metric popovers & call review

Codexis: the enzyme platform grew up, the balance sheet paid for it

Q3 revenue more than doubled and ECO Synthesis crossed into an innovator's own pilot plant — while the stock lost half its value in 90 trading days
CDXS · Earnings Call · 2026-11-12

Two stories, one quarter

Codexis reported the best operating quarter it has put up in years. Revenue of $19.3 million against $8.6 million a year earlier, product gross margin of 74.5%, net loss halved to $8.1 million, guidance of $72–76 million reiterated, and a fourth consecutive quarter described by the CEO as "on-target." The stock, meanwhile, has fallen 53% over the last 90 trading days, from $2.43 to roughly $1.14, leaving a $105 million market cap sitting 97% below its 2021 peak. That gap — between an operating inflection and a share-price collapse — is the whole story here, and it is not a mystery. It is a financing story sitting on top of a technology story. In the quarter Codexis raised $25 million of net proceeds from an equity offering, and this week closed a $60 million senior secured term loan, drawing $42.5 million to retire $42 million of existing debt, structured as 48 months interest-only followed by a 12-month amortization. Read plainly: the company sold stock and levered up so that current cash funds operations and capex through 2028. Liabilities-to-assets has climbed to 72.5%, up 12.8 points year over year. The equity is being asked to hold a science timeline while the balance sheet buys that timeline.

What genuinely changed: from chemistry to deployment

Strip out the financing and this quarter delivered three real technical events. First, scale: the ECO Synthesis platform produced multiple batches at 100-gram scale with crude purity above 90%, a threshold the sales chief called the industry's bar, and cycle times fell 40%. Second, a new capability — direct incorporation of tissue-targeting molecules inside the standard workflow, pushing the platform toward a genuine end-to-end oligonucleotide synthesis solution. Third, and most commercially meaningful, two signed agreements: a feasibility study with an siRNA pioneer seeking higher-purity fragments, and an evaluation agreement with a large biopharmaceutical company covering ligation of a late stage clinical asset plus a pilot-scale technology transfer. That last one is the change worth underlining. “This will be Codexis' first technology transfer of ECO Synthesis into an innovator's pilot scale manufacturing environment” — Britton Jimenez, Senior Vice President, Sales and Marketing · 2026-11-12 — as Britton Jimenez put it. For two years the adoption channel has run through CDMOs; this puts the platform, with its small footprint and aqueous process, inside a customer's own plant. It is also the point where Codexis joins a broader biotech conversation: across the recent reporter set, late-stage pipeline language is everywhere — ABCL, LQDA, GMAB, TAK — and Codexis is now speaking it with an asset attached rather than a concept. The scientific kicker was in the potency data. Two fully stereocontrolled antisense strands were converted into siRNA duplexes and tested in primary human hepatocytes: “the stereo-defined siRNAs showed three to fourfold greater potency while achieving comparable levels of maximum gene knockdown” — Stefan Lutz, Chief Scientific Officer · 2026-11-12. That converts stereochemical control from a manufacturing nicety into a potential therapeutic differentiator — lower dose, less material, possibly annual dosing. Worth noting the contrast with prior quarters: stereochemistry has been pitched for four straight calls, first as stereo control opportunity, then as analytical data. This is the first time the argument is biological rather than mechanical. The competitive case also sharpened into something concrete. Management now argues solid-phase chemistry carries physical limitations — roughly 7 to 10 kilos per batch — against a market that wants metric tons, and that the ECO route is about 70% more capital efficient. That is the pitch to the new CDMO prospect who is not currently in oligonucleotide manufacturing at all and wants to enter.

The promise that quietly became a hope

Here is where the tape and the transcript meet. Four quarters of CDMO momentum have not yet produced a signed commercial partnership — repeatedly signaled as imminent. In November 2025 the framing was landing a GMP scale-up partner; in August 2026 the lead CDMO was described as in active long-term negotiation:

1 has pretty much completed their entire assessment... which were in long-term commercial partnership negotiations currently... we are hoping to get that wrapped up here fairly quickly.

Britton Jimenez, Senior Vice President, Sales and Marketing · 2026-08-11
Three months later the update is procedural, not contractual: two of three evaluations complete, one still running, two new CDMOs engaged. And the timing language has softened into something close to a retreat: “Very difficult to predict the timing on those.” — Alison Moore, President and Chief Executive Officer · 2026-11-12 The funnel is real and management is candid — but the milestone that would validate the adoption thesis keeps sliding a quarter to the right. The same drift applies to scale. In August the target was explicit: “by the end of the year. We can be operating at about a half-kilo scale” — Alison Moore, President and Chief Executive Officer · 2026-08-11. In November that becomes "in the coming months, we will be moving toward 500-gram production scale." And the GMP facility — a fixture of the 2024 and 2025 keyword sets, repeatedly tied to the kilo scale story — now earns one closing sentence: construction begins. Not a reversal, but a theme whose prominence has shrunk precisely as the cash runway has.

What makes this a stock again

Two things. First, the base business is genuinely carrying the company while ECO matures: product sales up 78.5% for the first nine months, led by CDX-049, three approved drugs this year using Codexis enzymes, two of them potential blockbusters, and 12 programs in Phase II or III with seven readouts expected over two years. Gross margin of 74.5% in product is the reason full-year margin guidance was lifted toward the low 70s. Free cash flow improved 47% year over year even while the loss narrowed. Second, the arithmetic of guidance. Nine months in, revenue totals $49.3 million; hitting $72–76 million requires $23–27 million in Q4 against a 2025 Q4 of $39 million — the year's traditional lump. Doable, but it leans on the same unpredictability the CFO has flagged for six quarters about order timing on the biocatalysis side. The last filed quarter showed $15 million before Q3's step-up, against a 2022 peak of $35 million. So the setup is unusually clean for a microcap. Price-to-revenue near 2.7x says the market does not believe the licensing optionality exists. The company's own answer is 2027: higher-value contracts and licensing deals, contingent on two evaluations converting. Nothing in this quarter disproves the skeptics — but the potency data, the tissue-targeting chemistry, and the first innovator pilot plant are the first three items in a while that could prove them wrong.